Loading...

Chiasma

Nasdaq:CHMA
Snowflake Description

Flawless balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CHMA
Nasdaq
$242M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Chiasma, Inc., a clinical-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease in the United States, Europe, and internationally. The last earnings update was 48 days ago. More info.


Add to Portfolio Compare Print
  • Chiasma has significant price volatility in the past 3 months.
CHMA Share Price and Events
7 Day Returns
-4.8%
NasdaqGS:CHMA
1.8%
US Pharmaceuticals
1.4%
US Market
1 Year Returns
383.2%
NasdaqGS:CHMA
10.3%
US Pharmaceuticals
4.9%
US Market
CHMA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Chiasma (CHMA) -4.8% 17.6% 32.1% 383.2% 161.5% -
US Pharmaceuticals 1.8% 2.2% -1% 10.3% 13% 16.4%
US Market 1.4% 3.8% 3.5% 4.9% 44.8% 40.1%
1 Year Return vs Industry and Market
  • CHMA outperformed the Pharmaceuticals industry which returned 10.3% over the past year.
  • CHMA outperformed the Market in United States of America which returned 4.9% over the past year.
Price Volatility
CHMA
Industry
5yr Volatility vs Market

Value

 Is Chiasma undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Chiasma to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Chiasma.

NasdaqGS:CHMA Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 3 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 7.5%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGS:CHMA
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.64
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.641 (1 + (1- 21%) (0.12%))
0.76
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (0.8 * 5.96%)
7.5%

Discounted Cash Flow Calculation for NasdaqGS:CHMA using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Chiasma is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NasdaqGS:CHMA DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 7.5%)
2019 -34.85 Analyst x1 -32.42
2020 -44.45 Analyst x2 -38.46
2021 -36.90 Analyst x1 -29.70
2022 8.64 Analyst x2 6.47
2023 70.42 Analyst x2 49.05
2024 73.63 Est @ 4.57% 47.72
2025 76.59 Est @ 4.02% 46.17
2026 79.37 Est @ 3.63% 44.51
2027 82.04 Est @ 3.36% 42.80
2028 84.64 Est @ 3.17% 41.07
Present value of next 10 years cash flows $177.20
NasdaqGS:CHMA DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $84.64 × (1 + 2.73%) ÷ (7.5% – 2.73%)
$1,823.56
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $1,823.56 ÷ (1 + 7.5%)10
$884.94
NasdaqGS:CHMA Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $177.20 + $884.94
$1,062.15
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $1,062.15 / 31.77
$33.43
NasdaqGS:CHMA Discount to Share Price
Calculation Result
Value per share (USD) From above. $33.43
Current discount Discount to share price of $7.61
= -1 x ($7.61 - $33.43) / $33.43
77.2%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Chiasma is available for.
Intrinsic value
>50%
Share price is $7.61 vs Future cash flow value of $33.43
Current Discount Checks
For Chiasma to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Chiasma's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Chiasma's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Chiasma's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Chiasma's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:CHMA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-1.35
NasdaqGS:CHMA Share Price ** NasdaqGS (2019-06-25) in USD $7.61
United States of America Pharmaceuticals Industry PE Ratio Median Figure of 29 Publicly-Listed Pharmaceuticals Companies 18.19x
United States of America Market PE Ratio Median Figure of 3,095 Publicly-Listed Companies 17.73x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Chiasma.

NasdaqGS:CHMA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:CHMA Share Price ÷ EPS (both in USD)

= 7.61 ÷ -1.35

-5.64x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Chiasma is loss making, we can't compare its value to the US Pharmaceuticals industry average.
  • Chiasma is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Chiasma's expected growth come at a high price?
Raw Data
NasdaqGS:CHMA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -5.64x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
60%per year
United States of America Pharmaceuticals Industry PEG Ratio Median Figure of 21 Publicly-Listed Pharmaceuticals Companies 1.63x
United States of America Market PEG Ratio Median Figure of 2,133 Publicly-Listed Companies 1.53x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Chiasma, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Chiasma's assets?
Raw Data
NasdaqGS:CHMA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $1.06
NasdaqGS:CHMA Share Price * NasdaqGS (2019-06-25) in USD $7.61
United States of America Pharmaceuticals Industry PB Ratio Median Figure of 183 Publicly-Listed Pharmaceuticals Companies 3.24x
United States of America Market PB Ratio Median Figure of 5,255 Publicly-Listed Companies 1.79x
NasdaqGS:CHMA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:CHMA Share Price ÷ Book Value per Share (both in USD)

= 7.61 ÷ 1.06

7.16x

* Primary Listing of Chiasma.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Chiasma is overvalued based on assets compared to the US Pharmaceuticals industry average.
X
Value checks
We assess Chiasma's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Chiasma has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Chiasma expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
60%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Chiasma expected to grow at an attractive rate?
  • Chiasma's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Chiasma's earnings growth is expected to exceed the United States of America market average.
  • Unable to compare Chiasma's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:CHMA Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGS:CHMA Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 60%
United States of America Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 14.8%
United States of America Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5.4%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.9%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:CHMA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:CHMA Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 164 73 69 3
2022-12-31 106 10 31 2
2021-12-31 29 -34 -35 2
2020-12-31 2 -42 -45 3
2019-12-31 0 -16 -34 3
NasdaqGS:CHMA Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 -27 -33
2018-12-31 -24 -31
2018-09-30 -24 -29
2018-06-30 -24 -29
2018-03-31 -23 -27
2017-12-31 -24 -27
2017-09-30 -25 -29
2017-06-30 -34 -31
2017-03-31 -46 -51
2016-12-31 -52 -61
2016-09-30 -59 -68
2016-06-30 -51 -68

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Chiasma's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if Chiasma is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:CHMA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Chiasma Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:CHMA Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 1.64 2.62 0.59 3.00
2022-12-31 0.77 0.77 0.76 2.00
2021-12-31 -0.92 -0.58 -1.13 3.00
2020-12-31 -1.38 -1.37 -1.41 3.00
2019-12-31 -1.14 -1.04 -1.25 3.00
NasdaqGS:CHMA Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -1.35
2018-12-31 -1.28
2018-09-30 -1.20
2018-06-30 -1.18
2018-03-31 -1.10
2017-12-31 -1.10
2017-09-30 -1.17
2017-06-30 -1.28
2017-03-31 -2.09
2016-12-31 -2.51
2016-09-30 -2.79
2016-06-30 -2.92

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Chiasma will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Chiasma's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Chiasma has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Chiasma performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Chiasma's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Chiasma does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Chiasma's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Chiasma's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Chiasma's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Chiasma Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:CHMA Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 -32.97 9.99 23.97
2018-12-31 -31.26 9.97 22.36
2018-09-30 -29.29 9.11 20.95
2018-06-30 -28.67 9.11 20.18
2018-03-31 -26.85 9.12 18.16
2017-12-31 -26.83 9.15 17.95
2017-09-30 -28.62 9.90 18.42
2017-06-30 -31.14 11.53 40.25
2017-03-31 -50.95 14.28 35.97
2016-12-31 -61.11 21.82 31.32
2016-09-30 -67.75 25.54 26.53
2016-06-30 -67.77 26.47
2016-03-31 -49.06 24.52
2015-12-31 -36.23 16.46 18.99
2015-09-30 0.00 -30.55 12.24
2015-06-30 2.60 -20.61 7.44
2015-03-31 8.59 -8.99 4.55
2014-12-31 13.17 -2.92 3.47
2013-12-31 73.13 -5.36 7.67

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Chiasma has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Chiasma has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Chiasma improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Chiasma's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Chiasma has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Chiasma's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Chiasma's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Chiasma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Chiasma's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Chiasma's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are -9.6393244984387E+17x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Chiasma Company Filings, last reported 2 months ago.

NasdaqGS:CHMA Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 26.03 0.00 33.86
2018-12-31 34.12 0.00 41.66
2018-09-30 41.52 0.00 48.10
2018-06-30 48.20 0.00 54.63
2018-03-31 56.06 0.00 60.50
2017-12-31 62.47 0.00 66.94
2017-09-30 67.97 0.00 73.17
2017-06-30 74.10 0.00 80.11
2017-03-31 79.43 0.00 85.02
2016-12-31 85.73 0.00 92.98
2016-09-30 93.06 0.00 99.36
2016-06-30 101.79 0.00 115.63
2016-03-31 128.11 0.00 134.30
2015-12-31 142.82 0.00 148.75
2015-09-30 155.34 0.00 162.85
2015-06-30 57.06 0.00 63.27
2015-03-31 64.14 0.00 70.87
2014-12-31 32.47 0.00 40.16
2013-12-31 0.10 0.00 12.85
  • Chiasma's level of debt (0%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (0% vs 0% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Chiasma has sufficient cash runway for 1.2 years based on current free cash flow.
  • Chiasma has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of -33.3% each year.
X
Financial health checks
We assess Chiasma's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Chiasma has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Chiasma's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Chiasma dividends.
If you bought $2,000 of Chiasma shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Chiasma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Chiasma's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:CHMA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
United States of America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.7%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2012 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGS:CHMA Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Chiasma has not reported any payouts.
  • Unable to verify if Chiasma's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Chiasma's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Chiasma has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Chiasma's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Chiasma afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Chiasma has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Chiasma's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Raj Kannan
AGE 54
TENURE AS CEO 0 years
CEO Bio

Mr. Kannan has been Chief Executive Officer and Director at Kiniksa Pharmaceuticals, Ltd. since June 2019.

CEO Compensation
  • Insufficient data for Raj to compare compensation growth.
  • Insufficient data for Raj to establish whether their remuneration is reasonable compared to companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Chiasma management team in years:

2.6
Average Tenure
54
Average Age
  • The tenure for the Chiasma management team is about average.
Management Team

Mark Fitzpatrick

TITLE
President & Principal Financial Officer
COMPENSATION
$1M
AGE
55
TENURE
2.7 yrs

Drew Enamait

TITLE
VP of Administration and Principal Accounting Officer
COMPENSATION
$362K
AGE
44
TENURE
2.6 yrs

William Ludlam

TITLE
Senior Vice President of Clinical Development & Medical Affairs
COMPENSATION
$579K
AGE
53
TENURE
2.4 yrs

Raj Kannan

TITLE
CEO & Director
AGE
54

Gary Patou

TITLE
Head of Clinical
AGE
59
TENURE
3.3 yrs
Board of Directors Tenure

Average tenure and age of the Chiasma board of directors in years:

4.3
Average Tenure
55.5
Average Age
  • The tenure for the Chiasma board of directors is about average.
Board of Directors

Dave Stack

TITLE
Chairman
COMPENSATION
$85K
AGE
68
TENURE
4.6 yrs

Raj Kannan

TITLE
CEO & Director
AGE
54

Chip Scarlett

TITLE
Independent Director
COMPENSATION
$65K
AGE
67
TENURE
4.3 yrs

John Thero

TITLE
Director
COMPENSATION
$62K
AGE
57
TENURE
3.6 yrs

Bard Geesaman

TITLE
Independent Director
COMPENSATION
$47K
AGE
51
TENURE
15.4 yrs

Roni Mamluk

TITLE
Director
COMPENSATION
$135K
AGE
51
TENURE
2 yrs

Todd Foley

TITLE
Director
COMPENSATION
$56K
AGE
46
TENURE
11.1 yrs

Scott Minick

TITLE
Director
COMPENSATION
$69K
AGE
66
TENURE
11.7 yrs

Shlomo Melmed

TITLE
Member of Clinical Advisory Committee
TENURE
3.4 yrs

Christian Strasburger

TITLE
Member of Clinical Advisory Committee
TENURE
3.4 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
21. Sep 18 Buy Scott Minick Individual 18. Sep 18 20. Sep 18 25,000 $3.09 $76,930
X
Management checks
We assess Chiasma's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Chiasma has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

One Thing To Remember About The Chiasma, Inc. (NASDAQ:CHMA) Share Price

Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). … Given that it has a beta of 1.2, we can surmise that the Chiasma share price has been fairly sensitive to market volatility (over the last 5 years). … What this means for you: Since Chiasma tends to moves up when the market is going up, and down when it's going down, potential investors may wish to reflect on the overall market, when considering the stock.

Simply Wall St -

What Kind Of Shareholders Own Chiasma, Inc. (NASDAQ:CHMA)?

Insider Ownership Of Chiasma The definition of an insider can differ slightly between different countries, but members of the board of directors always count. … Insider ownership is positive when it signals leadership are thinking like the true owners of the company. … But other times, private equity is selling out, having taking the company public.

Simply Wall St -

Need To Know: Chiasma, Inc. (NASDAQ:CHMA) Insiders Have Been Buying Shares

In the last twelve months, the biggest single purchase by an insider was when Director Scott Minick bought US$77k worth of shares at a price of US$3.09 per share … Even though the purchase was made at a significantly lower price than the recent price (US$5.84), we still think insider buying is a positive … Because the shares were purchased at a lower price, this particular buy doesn't tell us much about how insiders feel about the current share price

Simply Wall St -

The Chiasma Share Price Has Gained 156%, So Why Not Pay It Some Attention?

(NASDAQ:CHMA) share price had more than doubled in just one year - up 156%. … Companies that lack both meaningful revenue and profits are usually considered high risk. … There is almost always a chance they will need to raise more capital, and their progress - and share price - will dictate how dilutive that is to current holders.

Simply Wall St -

Chiasma, Inc. (NASDAQ:CHMA): What Does Its Beta Value Mean For Your Portfolio?

Every stock in the market is exposed to this volatility, which is linked to the fact that stocks prices are correlated in an efficient market. … Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). … Any stock with a beta of greater than one is considered more volatile than the market, while those with a beta below one are either less volatile or poorly correlated with the market.

Simply Wall St -

Who Has Been Buying Chiasma, Inc. (NASDAQ:CHMA) Shares?

So we'll take a look at whether insiders have been buying or selling shares in Chiasma, Inc. … The Last 12 Months Of Insider Transactions At Chiasma. … Scott Minick was the only insider to buy shares in the last twelve months

Simply Wall St -

How Many Chiasma Inc (NASDAQ:CHMA) Shares Do Institutions Own?

Generally speaking, as a company grows, institutions will increase their ownership. … Chiasma is a smaller company with a market capitalization of US$90m, so it may still be flying under the radar of many institutional investors. … institutional investors have bought into the company.

Simply Wall St -

Should You Be Concerned About Chiasma Inc's (NASDAQ:CHMA) Shareholders?

Today, I will be analyzing Chiasma Inc’s (NASDAQ:CHMA) recent ownership structure, an important but not-so-popular subject among individual investors. … The impact of a company's ownership structure affects both its short- and long-term performance. … The same amount of capital coming from an activist institution and a passive mutual fund has different implications on corporate governance, which is a decisive factor for a long-term investor.

Simply Wall St -

Who Are The Major Shareholders Of Chiasma Inc (NASDAQ:CHMA)?

See our latest analysis for Chiasma NasdaqGS:CHMA Ownership_summary Apr 4th 18 Institutional Ownership Institutions account for 26.69% of CHMA's outstanding shares, a significant enough holding to move stock prices if they start buying and selling in large quantities, especially when there are relatively small amounts of shares available on the market to trade. … For shareholders in CHMA, sharp price movements may not be a major concern as active hedge funds hold a relatively small stake in the company. … This is a positive sign for potential investors as these firms play an important role in aligning company policy with shareholder returns.Next Steps: The company's high institutional ownership makes margin of safety a very important consideration to existing investors since long bull and bear trends often emerge when these big-ticket investors see a change in long-term potential of the company.

Simply Wall St -

Does Chiasma Inc (NASDAQ:CHMA) Go Up With The Market?

A popular measure of market risk for a stock is its beta, and the market as a whole represents a beta value of one. … Chiasma has a beta of 1.03, which means that the percentage change in its stock value will be higher than the entire market in times of booms and busts. … An asset-heavy company tends to have a higher beta because the risk associated with running fixed assets during a downturn is highly expensive.

Simply Wall St -

Company Info

Description

Chiasma, Inc., a clinical-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease in the United States, Europe, and internationally. The company offers oral octreotide capsules for adult patients under the MYCAPSSA name, which is in two Phase III clinical trials for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone. Chiasma, Inc. was founded in 2001 and is headquartered in Waltham, Massachusetts.

Details
Name: Chiasma, Inc.
CHMA
Exchange: NasdaqGS
Founded: 2001
$241,753,833
31,767,915
Website: http://www.chiasmapharma.com
Address: Chiasma, Inc.
460 Totten Pond Road,
Suite 530,
Waltham,
Massachusetts, 02451,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS CHMA Common Stock Nasdaq Global Select US USD 16. Jul 2015
DB CXS Common Stock Deutsche Boerse AG DE EUR 16. Jul 2015
Number of employees
Current staff
Staff numbers
18
Chiasma employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/26 00:53
End of day share price update: 2019/06/25 00:00
Last estimates confirmation: 2019/06/19
Last earnings filing: 2019/05/09
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.